![Analysis of Mass Spec data (dashed-line) of fractions stained with CPS1 / Carbamoyl-Phosphate Synthetase MS-QAVA™ monoclonal antibody [Clone: CPS1/1022] (solid-line), reveals that less than 0.5% of signal is attributable to non-specific binding of anti-CPS1 / Carbamoyl-Phosphate Synthetase [Clone CPS1/1022] to targets other than CPS1 protein. Even frequently cited antibodies have much greater non-specific interactions, averaging over 30%. Data in image is from analysis in Jurkat, U202 and HeLa cells.](https://cdn-enquirebio.pressidium.com/wp-content/uploads/2017/10/enQuire-Bio-1373-MSM1-P1-anti-CPS1-Carbamoyl-Phosphate-Synthetase-antibody.png "CPS1 / Carbamoyl-Phosphate Synthetase Antibody Mass Spec Validation Data")
PDF DatasheetHuman Anti-CPS1 / Carbamoyl-Phosphate Synthetase Antibody Product Attributes
CPS1 / Carbamoyl-Phosphate Synthetase Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Variations in CPS1 / Carbamoyl-Phosphate Synthetase antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in glandular cells in the duodenum and small intestine and hepatocytes in liver. More moderate antibody staining intensity was present in glandular cells in the duodenum and small intestine and hepatocytes in liver. Low, but measureable presence of CPS1 / Carbamoyl-Phosphate Synthetase could be seen in. We were unable to detect CPS1 / Carbamoyl-Phosphate Synthetase in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Type:
Tissues from cancer patients, for instance, have their own distinct pattern of CPS1 / Carbamoyl-Phosphate Synthetase expression as measured by anti-CPS1 / Carbamoyl-Phosphate Synthetase antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | ++ | – | – | – | – | – | – | – | – | – | – | – | – |
| CPS1 Variability | + | + | + | + | + | + | + | ++ | + | + | + | + | ++ | + | + | + | ++ | + | + | + |
| CPS1 / Carbamoyl-Phosphate Synthetase General Information | |
|---|---|
| Alternate Names | |
| Calcitonin, thyrocalcitonin, CALCA | |
| Molecular Weight | |
| ~165kDa | |
| Chromosomal Location | |
| 2q35 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CPS1 |
| Entrez Gene ID | 1373 |
| Ensemble Gene ID | ENSG00000021826 |
| RefSeq Protein Accession(s) | NP_001116106, XP_011508942, XP_011508944, NP_001866, XP_011508946, NP_001116105, XP_011508943, XP_011508945 |
| RefSeq mRNA Accession(s) | NM_001122633, XM_011510640, XM_011510642, NM_001122634, XM_011510644, NM_001875, XM_011510643 |
| RefSeq Genomic Accession(s) | NG_008285, NC_018913, NC_000002 |
| UniProt ID(s) | A0A024R454, P31327, B7ZAW0, Q6PEK7 |
| UniGene ID(s) | A0A024R454, P31327, B7ZAW0, Q6PEK7 |
| HGNC ID(s) | 2323 |
| Cosmic ID(s) | CPS1 |
| KEGG Gene ID(s) | hsa:1373 |
| PharmGKB ID(s) | PA26840 |
| General Description of CPS1 / Carbamoyl-Phosphate Synthetase. | |
| This MAb recognizes a protein of 165kDa, identified as carbamoyl phosphate synthetase 1 (CPS1). This mitochondrial enzyme catalyzes synthesis of carbamoyl phosphate from ammonia, bicarbonate. This reaction is the first committed step of the urea cycle, which is important in the removal of excess urea from cells.Deficiency of CPS1 is an autosomal recessive disorder that causes hyperammonemia. CPS1 is a hepatocyte specific protein that localizes to the mitochondria of hepatocytes. It is a sensitive marker for distinguishing hepatocellular carcinomas (HCC) from other metastatic carcinomas as well as cholangio-carcinomas. HCC s occur primarily in the stomach, but they are also found in many other organs. CPS1 may also be a useful marker for intestinal metaplasia. Reportedly, strong expression of CPS1 correlates with smaller tumor size, longer patient survival. Occasionally, CPS1 is also found in gastric carcinomas as well as in a few other non-hepatic tumors. | |
There are no reviews yet.